Back to Search Start Over

Nicotinamide provides neuroprotection in glaucoma by protecting against mitochondrial and metabolic dysfunction

Authors :
Alberto Domínguez-Vicent
James R. Tribble
Emma Lardner
Robert W. Burgess
Jonathan G Crowston
Eirini Kokkali
Marcela Votruba
Melissa Jöe
Gloria Cimaglia
Shanshan Sun
Peter G. Fuerst
Gauti Jóhannesson
Rupali Vohra
Rune Brautaset
Seungsoo Rho
Miriam Kolko
Amin Otmani
Abinaya Priya Venkataraman
Sevannah A. Ellis
Peter A. Williams
James E. Morgan
Source :
Redox Biology, Vol 43, Iss, Pp 101988-(2021), Tribble, J R, Otmani, A, Sun, S, Ellis, S A, Cimaglia, G, Vohra, R, Jöe, M, Lardner, E, Venkataraman, A P, Domínguez-Vicent, A, Kokkali, E, Rho, S, Jóhannesson, G, Burgess, R W, Fuerst, P G, Brautaset, R, Kolko, M, Morgan, J E, Crowston, J G, Votruba, M & Williams, P A 2021, ' Nicotinamide provides neuroprotection in glaucoma by protecting against mitochondrial and metabolic dysfunction ', Redox Biology, vol. 43, 101988 . https://doi.org/10.1016/j.redox.2021.101988
Publication Year :
2021
Publisher :
Elsevier, 2021.

Abstract

Nicotinamide adenine dinucleotide (NAD) is a REDOX cofactor and metabolite essential for neuronal survival. Glaucoma is a common neurodegenerative disease in which neuronal levels of NAD decline. Repleting NAD via dietary supplementation of nicotinamide (a precursor to NAD) is effective in preventing retinal ganglion cell neurodegeneration in mouse models. Supporting this, short-term oral nicotinamide treatment in human glaucoma patients provides a recovery of retinal ganglion cell function implying a protection of visual function. Despite this, the mechanism of neuroprotection and full effects of nicotinamide on retinal ganglion cells is unclear. Glaucoma is a complex neurodegenerative disease in which a mix of healthy, stressed, and degenerating retinal ganglion cells co-exist, and in which retinal ganglion cells display compartmentalized degeneration across their visual trajectory. Therefore, we assess the effects of nicotinamide on retinal ganglion cells in normal physiological conditions and across a range of glaucoma relevant insults. We confirm neuroprotection afforded by nicotinamide in rodent models which represent isolated ocular hypertensive, axon degenerative, and mitochondrial degenerative insults. We define a small molecular weight metabolome for the retina, optic nerve, and superior colliculus which demonstrates that ocular hypertension induces widespread metabolic disruption that can be prevented by nicotinamide. Nicotinamide provides these neuroprotective effects by increasing oxidative phosphorylation, buffering and preventing metabolic stress, and increasing mitochondrial size and motility whilst simultaneously dampening action potential firing frequency. These data support continued determination of the utility of long-term NAM treatment as a neuroprotective therapy for human glaucoma.One Sentence SummaryThe NAD precursor nicotinamide has a potent neuroprotective effect in the retina and optic nerve, targeting neuronal function, metabolism, and mitochondrial function.

Details

Language :
English
ISSN :
22132317
Volume :
43
Database :
OpenAIRE
Journal :
Redox Biology
Accession number :
edsair.doi.dedup.....f2b7262f22fb5249dc95c75d737e8e19